BiotechTube

ONO-4474 + Placebo matching ONO-4474

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoarthritis, Knee

Conditions

Osteoarthritis, Knee, Pain

Trial Timeline

Jan 1, 2017 → Jan 9, 2018

NCT ID
NCT02997696

About ONO-4474 + Placebo matching ONO-4474

ONO-4474 + Placebo matching ONO-4474 is a phase 2 stage product being developed by Ono Pharmaceutical for Osteoarthritis, Knee. The current trial status is terminated. This product is registered under clinical trial identifier NCT02997696. Target conditions include Osteoarthritis, Knee, Pain.

What happened to similar drugs?

20 of 20 similar drugs in Osteoarthritis, Knee were approved

Approved (20) Terminated (1) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Capsaicin Topical SolutionAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅ImrecoxibJiangsu Hengrui MedicineApproved
✅Etoricoxib (Arcoxia) + Sugar pillMerckApproved
✅zoledronic acidNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02997696Phase 2Terminated

Competing Products

20 competing products in Osteoarthritis, Knee

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43
UBX0101 or placeboUnity BiotechnologyPre-clinical
8
UBX0101Unity BiotechnologyPhase 1
19
UBX0101Unity BiotechnologyPhase 2
25
UBX0101Unity BiotechnologyPhase 1
19
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
35
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
35
Capsaicin Topical SolutionAstellas PharmaApproved
43
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
DuloxetineShionogiPhase 3
40
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part DOno PharmaceuticalPhase 1
29
Duloxetine + PlaceboEli LillyPhase 3
40